Belgium· BE-AMP-SAM382575-00
Verliret 2 mg
A pitavastatin product containing pitavastatin calcium, registered in Belgium by Kowa Pharmaceutical Europe Co.. The same ATC class is registered in 12 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Pitavastatin is registered in 12 of 19 countries.
Countries holding a registration under ATC C10AA08 (pitavastatin), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 9 of them publish a price we can compare per daily dose
Pitavastatin · ATC C10AA08
12 / 19 countries
- Belgiumprice
- Czechiaprice
- Finlandprice
- Franceprice
- Germany
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Statesprice
Price per daily dose
What a daily dose of pitavastatin costs, country by country.
Normalised to the WHO defined daily dose (2 mg), the median price runs from $0.43 in Spain to $3.35 in United States — a ×7.7 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Pitavastatin · price per daily dose (2 mg)
USD · FX 28 Sept 2026
- US United States$3.35 (acquisition cost)
- CH Switzerland$1.57
- ES Spain$0.43
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Pitavastatin Calcium
- Manufacturer
- Kowa Pharmaceutical Europe Co.
- Country
- Belgium (BE)
- ATC code
- C10AA08
- ATC class
- Pitavastatin
- Defined daily dose
- 2 mg, O
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
116 interactions on record for pitavastatin.
Graded by severity as the source publishes them — 7 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Pitavastatin · interactions on record
116 records
- 7 severe
- 103 moderate
- 2 minor
Most severe, free to view
- ErythromycinJ01FA01severe
- LeflunomidL04AA13severe
- TeriflunomidL04AA31severe
- CiclosporinL04AD01severe
4 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Pitavastatin in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaPITILOXKrka, d.d., Novo mesto, Novo mesto
- SpainALIPZA 2 mg COMPRIMIDOS RECUBIERTOS CON PELICULAKowa Pharmaceutical Europe Gmbh
- SwitzerlandLivazo 2 mg, FilmtablettenRECORDATI AG
- United StatesPitavastatinAurobindo Pharma Limited
- PolandLivazoKowa Pharmaceutical Europe GmbH
- FranceLIPPIZA 2 mg, comprimé pelliculéKOWA PHARMACEUTICAL EUROPE (ALLEMAGNE)
- NetherlandsLivazo 2 mg filmomhulde tablettenKowa Pharmaceutical Europe GmbH
- FinlandLivazoKowa Pharmaceutical Europe GmbH.
Authorised across Europe · EMA
The same active substance is authorised in 20 EEA countries. Names it is sold under:
- Austria · Trolise
- Bulgaria · Липоканте, Питавиа
- Cyprus · Vaspit
- Czechia · Pitilox
- Germany · Livazo, Pitavastatin
- Spain · Alipza, Lipix
- France · Lippiza, Trolise
- Greece · Fiarat, Livazo
- Hungary · Pitilox
- Ireland · Livazo
- Italy · Livazo
- Lithuania · Pitipix
- Malta · Vaspit
- Netherlands · Livazo
- Norway · Livazo
- Poland · Livazo, Pitamet
- Portugal · Alipza, Livazo
- Romania · Pitipix
- Slovenia · Pitipix
- Slovakia · Pitipix
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/655f17f8-1695-439c-a401-afe1f9d8c20f GET /v1/drugs/655f17f8-1695-439c-a401-afe1f9d8c20f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Film-coated tablet",
"source": "afmps",
"status": "REVOKED",
"name_en": "Verliret 2 mg",
"name_fr": "Verliret 2 mg",
"name_nl": "Verliret 2 mg",
"amp_code": "SAM382575-00",
"strengths": [
"2.0000"
],
"pack_count": 5,
"substances": [
"Pitavastatin Calcium",
"Pitavastatin"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Pitavastatin",
"authorisation_numbers": [
"BE382575"
]
}See everything about pitavastatin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.